Guangzhou Kingmed Diagnostics Group Co Ltd

On October 10, the AI-Empowered Precision Diagnosis and Treatment of Lung Cancer Summit Forum and the launch ceremony for the National Respiratory Medicine Center's Lung Cancer Precision Diagnosis and Treatment Standardization Project, hosted by the National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University and the Guangdong Provincial Chest Disease Society, and organized by KingMed Diagnostics, was held in Guangzhou. At the event, DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics jointly developed by the First Affiliated Hospital of Guangzhou Medical University and KingMed Diagnostics, was officially released. A multicenter research project involving 50 medical institutions nationwide was also launched, marking the model's formal entry into large-scale clinical validation. According to Dr. Liu Si, head of KingMed Diagnostics' artificial intelligence division, DeepGEM 2.0 analyzes routine digital pathology slide images without requiring additional sampling and can deliver results in as little as one minute. Building on the original six genes—EGFR, KRAS, ALK, ROS1, TP53, and LRP1B—it adds BRAF, ERBB2, FGFR, MET, NTRK, and RET, bringing the total to 12 genes and achieving full coverage of genes corresponding to approved targeted therapies for lung cancer in China. The model will subsequently be deployed in a lightweight form at more than 500 medical institutions. Using an approach of AI-based initial screening combined with targeted validation of specific genes, it is expected to reduce the cost of lung cancer genetic testing to the range of several hundred yuan. Zhong Nanshan, an academician of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory, said that in the new AI era, scientific research must aim high while serving the people. In 2025, the First Affiliated Hospital of Guangzhou Medical University, together with KingMed Diagnostics and Tencent, released DeepGEM, a multimodal pathology genomics model capable of identifying genes from images. After nearly a year of multicenter data validation and clinical refinement, and iterative optimization using nearly 8,000 digital pathology slides from 31 provinces across China provided by KingMed Diagnostics, it has been upgraded to version 2.0. Liang Yaoming, chairman and CEO of KingMed Diagnostics, said that AI pathology technology brings new opportunities to narrow regional disparities in diagnosis and treatment and to reduce costs while improving efficiency. KingMed Diagnostics will leverage the network advantages of its nationwide intelligent medical diagnostic service platform to bring innovative pathology AI technology to primary-level healthcare.

On September 24, major A-share indices opened lower, while the media sector bucked the trend in early trading. Xinhua Winshare hit its fifth consecutive limit-up, Xinhua Media its fourth, and Topway Video its third, with Guangdong Media and Inner Mongolia Xinhua Distribution also among the top gainers. In news, Xinhua Winshare recently announced plans to use its own funds to acquire the 100% equity stake in Sichuan Nationalities Publishing House held by its controlling shareholder, Sichuan Xinhua Publishing and Distribution Group, for 346 million yuan. The transaction constitutes a related-party transaction but does not constitute a major asset restructuring. On the same day, Bairui Gene debuted on the Beijing Stock Exchange, opening 347.23% higher and rising more than 400% as of press time, with an issue price of 16.77 yuan. The company focuses on the research, production, and sales of biomedical materials and other products. The AI-driven drug discovery concept saw a sudden surge, with Berry Genomics hitting the daily limit-up in a straight line, and BGI Genomics, Rongtai Health, Saili Medical, Sino Biological, and Kingmed Diagnostics following higher. This came after the Ministry of Industry and Information Technology and nine other departments jointly issued the 15th Five-Year Plan for the development of the pharmaceutical industry, which explicitly calls for accelerating the use of artificial intelligence and other new technologies to empower drug research and development. The coal sector fluctuated higher, with Yunnan Coal Energy hitting the daily limit-up, briefly opening, and then sealing the limit-up again. Zhengzhou Coal Mining Machinery, Liaoning Energy, Antai Group, and Shaanxi Heimao followed higher. On September 24, the benchmark price for thermal coal on SunSirs was 989.50 yuan per ton, up 13.02% from 875.50 yuan per ton at the beginning of the month. The robotics concept saw localized movement, with Xiangyang Automobile Bearing hitting the limit-up, and Ningbo Dongli, Wanxiang Qianchao, Nanfang Precision, Sanhua Intelligent Controls, and Tuopu Group following higher. Tesla CEO Elon Musk said in an interview on September 23 that he predicts there will be at least 1 billion humanoid robots within 10 years or less, perhaps 10 billion in the next 15 years, and possibly 100 billion in the next 20 years. The real estate sector fell sharply, with Huali Family hitting the limit-down, Huayuan Holdings touching the limit-down, and Greenland Holdings, Heungkong Holdings, China Vanke, and Risesun Development quickly following lower.

KingMed Diagnostics released its 2026 interim report, showing a net profit attributable to shareholders of 190 million yuan for the first half, swinging from a loss in the same period last year. Revenue was 2.88 billion yuan, down 3.8 percent year on year. Net profit attributable to shareholders excluding non-recurring items was 203 million yuan, compared with a loss of 97.96 million yuan a year earlier. Net operating cash flow was 243 million yuan, down 30.8 percent year on year. Second-quarter revenue was 1.53 billion yuan, up 0.2 percent year on year, with net profit attributable to shareholders of 147 million yuan. The company said that against the backdrop of healthcare reform, an ageing population and the development of county-level medical systems, the third-party medical testing industry is adjusting its pricing methods, service scenarios and capability structure. KingMed has set a medium- and long-term strategic goal of building a globally leading smart service platform for medical diagnostics.

KingMed Diagnostics announced that as of July 31, 2026, the company had repurchased 6.77 million shares, accounting for 1.46% of total share capital, with a total repurchase amount of 178 million yuan, at a price range of 23.36 yuan to 28.79 yuan per share. In the first quarter of 2026, the company achieved revenue of 1.351 billion yuan and net profit attributable to the parent company of 42.79 million yuan.